Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.

NCT06376773 | Completed DMC

• 1 other identifier: 2022KY123
• Study Type: observational
• Target: 234
• Locations: 1 country
• Sites: 1

Brief Summary

Extensive research employing diverse omics methodologies has unveiled a varied landscape of gastric cancer (GC). Recent progress in next-generation sequencing and other genomic technologies has facilitated a more intricate exploration of GC at the molecular level. This study aimed to identify the most effective drug therapeutics for patients with the mesenchymal subtype of gastric cancer.Based on RNA-seq transcriptome, 234 patients were divided into four molecular subtypes: mesenchymal, immunogenic, metabolic, and classic.Our analysis has revealed that, for neoadjuvant therapy in advanced gastric cancer (AGC), the mesenchymal subtype stands out as the ideal patient population benefiting from Apatinib, without a concurrent increase in postoperative complications.

Conditions

Advanced Gastric Cancer; Neoadjuvant Therapy; Multi-omics Analysis

Outcome Measures

Primary Outcomes (1)

• overall survival

  overall survival

  2years

Secondary Outcomes (1)

• objective response rate

  6months

Study Arms (4)

mesenchymal

Based on RNA-seq transcriptome, patients were divided into mesenchymal, and received neoadjuvant chemotherapy with apatinib or not

Procedure: combination chemotherapy with Apatinib or Camrelizumab

immunogenic

Based on RNA-seq transcriptome, patients were divided into immunogenic, and received neoadjuvant chemotherapy with Camrelizumab or not

Procedure: combination chemotherapy with Apatinib or Camrelizumab

metabolic

Based on RNA-seq transcriptome, patients were divided into metabolic, and received neoadjuvant chemotherapy with apatinib, Camrelizumab or not

classic

Based on RNA-seq transcriptome, patients were divided into classic, and received neoadjuvant chemotherapy with apatinib, Camrelizumab or not

Interventions

combination chemotherapy with Apatinib or Camrelizumab PROCEDURE

Apatinib, chemotherapy alone, Camrelizumab

Also known as: mesenchymal, immunogenic, metabolic, classic

immunogenic; mesenchymal

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

This study collected data from 234 patients diagnosed with gastric adenocarcinoma at Fujian Medical University Union Hospital (FMUUH) who underwent gastrectomy after receiving neoadjuvant therapy (NAT) between January 2019 and January 2022.

You may qualify if:

• diagnosed with gastric adenocarcinoma and received neoadjuvant therapy

You may not qualify if:

• Patients with distant metastases, gastric stump cancer, or missing neoadjuvant chemotherapy data were excluded from the study.

Sponsors & Collaborators

• Fujian Medical University: lead

Study Sites (1)

Fujian Medical University Union Hospital

Fuzhou, Fuji'an, 350000, China

Location

MeSH Terms

Interventions

Drug Therapy, Combination; apatinib; camrelizumab; Metabolic Networks and Pathways; Congresses as Topic

Intervention Hierarchy (Ancestors)

Drug Therapy; Therapeutics; Metabolism; Organizations; Health Care Economics and Organizations

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Fujian Medical University

Study Record Dates

• First Submitted: April 15, 2024
• First Posted: April 19, 2024
• Study Start: June 1, 2022
• Primary Completion: July 1, 2023
• Study Completion: November 30, 2023
• Last Updated: April 19, 2024

Record last verified: 2024-04

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)